journal
https://read.qxmd.com/read/38423784/development-and-preclinical-evaluation-of-211-at-psat-3-ga-an-inhibitor-for-targeted-%C3%AE-therapy-of-prostate-cancer
#81
JOURNAL ARTICLE
Mohamed El Fakiri, Nawal Ayada, Marius Müller, Lars Hvass, Teodor H Gamzov, Anne Skovsbo Clausen, Nicolas M Geis, Nils Steinacker, Ellinor Hansson, Sture Lindegren, Emma Aneheim, Holger Jensen, Ann-Christin Eder, Andreas I Jensen, Christian B M Poulie, Andreas Kjaer, Matthias Eder, Matthias M Herth
The application of prostate-specific membrane antigen (PSMA)-targeted α-therapy is a promising alternative to β- -particle-based treatments. 211 At is among the potential α-emitters that are favorable for this concept. Herein, 211 At-based PSMA radiopharmaceuticals were designed, developed, and evaluated. Methods: To identify a 211 At-labeled lead, a surrogate strategy was applied. Because astatine does not exist as a stable nuclide, it is commonly replaced with iodine to mimic the pharmacokinetic behavior of the corresponding 211 At-labeled compounds...
February 29, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38423783/first-in-human-212-pb-psma-targeted-%C3%AE-therapy-spect-ct-imaging-in-a-patient-with-metastatic-castration-resistant-prostate-cancer
#82
JOURNAL ARTICLE
Matthew R Griffiths, David A Pattison, Melissa Latter, Kevin Kuan, Stephen Taylor, William Tieu, Thomas Kryza, Danielle Meyrick, Boon Quan Lee, Aaron Hansen, Stephen E Rose, Simon G Puttick
No abstract text is available yet for this article.
February 29, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38423782/radiolabeled-somatostatin-receptor-antagonist-versus-agonist-for-peptide-receptor-radionuclide-therapy-in-patients-with-therapy-resistant-meningioma-promenade-phase-0-study
#83
JOURNAL ARTICLE
Christopher Eigler, Lisa McDougall, Andreas Bauman, Peter Bernhardt, Michael Hentschel, Kristine A Blackham, Guillaume Nicolas, Melpomeni Fani, Damian Wild, Dominik Cordier
Our primary aim was to compare the therapeutic index (tumor-to-bone marrow and tumor-to-kidney absorbed-dose ratios) of the new radiolabeled somatostatin receptor antagonist [177 Lu]Lu-DOTA-JR11 with the established radiolabeled somatostatin receptor agonist [177 Lu]Lu-DOTATOC in the same patients with progressive, standard therapy-refractory meningioma. Methods: In this prospective, single-center, open-label phase 0 study (NCT04997317), 6 consecutive patients were included: 3 men and 3 women (mean age, 63...
February 29, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38423781/the-impact-of-baseline-psma-pet-ct-versus-ct-on-outcomes-of-223-ra-therapy-in-metastatic-castration-resistant-prostate-cancer-patients
#84
JOURNAL ARTICLE
Dianne Bosch, Kim J M van der Velden, Irma M Oving, Dirk N J Wyndaele, Leo E Weijs, W Dick van Schelven, Wim J G Oyen, Erik T Te Beek, Addy C M van de Luijtgaarden, Diederik M Somford, James Nagarajah, Rick Hermsen, Niven Mehra, Winald R Gerritsen, Maarten J van der Doelen, Inge M van Oort
Imaging before 223 Ra-dichloride (223 Ra) therapy is crucial for selecting metastatic castration-resistant prostate cancer (mCRPC) patients with bone-only disease. The purpose of this study was to evaluate if baseline prostate-specific membrane antigen (PSMA) PET/CT (bPSMA) versus CT is associated with outcomes of 223 Ra therapy. Methods: A secondary analysis of the data of a prospective observational study (NCT04995614) was performed. Patients received a maximum of 6 223 Ra cycles and were retrospectively divided into the bPSMA or baseline CT (bCT) groups...
February 29, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38388517/first-in-human-safety-imaging-and-dosimetry-of-a-carbonic-anhydrase-ix-targeting-peptide-68-ga-ga-dpi-4452-in-patients-with-clear-cell-renal-cell-carcinoma
#85
JOURNAL ARTICLE
Michael S Hofman, Ben Tran, Darren R Feldman, Anna Pokorska-Bocci, Solen Pichereau, Jonathan Wessen, Mohammad B Haskali, Richard B Sparks, Olena Vlasyuk, Ivana Galetic
[68 Ga]Ga-DPI-4452, a first-in-class carbonic anhydrase IX-binding radiolabeled peptide, is the imaging agent of a theranostic pair with [177 Lu]Lu-DPI-4452, developed for selecting and treating patients with carbonic anhydrase IX-expressing tumors. Here, [68 Ga]Ga-DPI-4452 imaging characteristics, dosimetry, pharmacokinetics, and safety were assessed in 3 patients with clear cell renal cell carcinoma. Methods: After [68 Ga]Ga-DPI-4452 administration, patients underwent serial full-body PET/CT imaging. Blood and urine were sampled...
February 22, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38388516/clinical-evaluation-of-deep-learning-for-tumor-delineation-on-18-f-fdg-pet-ct-of-head-and-neck-cancer
#86
JOURNAL ARTICLE
David G Kovacs, Claes N Ladefoged, Kim F Andersen, Jane M Brittain, Charlotte B Christensen, Danijela Dejanovic, Naja L Hansen, Annika Loft, Jørgen H Petersen, Michala Reichkendler, Flemming L Andersen, Barbara M Fischer
Artificial intelligence (AI) may decrease 18 F - FDG PET/CT-based gross tumor volume (GTV) delineation variability and automate tumor-volume-derived image biomarker extraction. Hence, we aimed to identify and evaluate promising state-of-the-art deep learning methods for head and neck cancer (HNC) PET GTV delineation. Methods: We trained and evaluated deep learning methods using retrospectively included scans of HNC patients referred for radiotherapy between January 2014 and December 2019 (ISRCTN16907234). We used 3 test datasets: an internal set to compare methods, another internal set to compare AI-to-expert variability and expert interobserver variability (IOV), and an external set to compare internal and external AI-to-expert variability...
February 22, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38388515/is-18-f-fdg-metabolic-tumor-volume-in-lymphoma-really-happening
#87
JOURNAL ARTICLE
Sally F Barrington, Anne-Ségolène Cottereau, Josée M Zijlstra
No abstract text is available yet for this article.
February 22, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38388514/mird-pamphlet-no-29-mirdy90-a-90-y-research-microsphere-dosimetry-tool
#88
JOURNAL ARTICLE
Harry Marquis, Juan C Ocampo Ramos, Lukas M Carter, Pat Zanzonico, Wesley E Bolch, Richard Laforest, Adam L Kesner
90 Y-microsphere radioembolization has become a well-established treatment option for liver malignancies and is one of the first U.S. Food and Drug Administration-approved unsealed radionuclide brachytherapy devices to incorporate dosimetry-based treatment planning. Several different mathematical models are used to calculate the patient-specific prescribed activity of 90 Y, namely, body surface area (SIR-Spheres only), MIRD single compartment, and MIRD dual compartment (partition). Under the auspices of the MIRDsoft initiative to develop community dosimetry software and tools, the body surface area, MIRD single-compartment, MIRD dual-compartment, and MIRD multicompartment models have been integrated into a MIRDy90 software worksheet...
February 22, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38388513/performance-evaluation-of-the-umi-panorama-pet-ct-system-in-accordance-with-the-national-electrical-manufacturers-association-nu-2-2018-standard
#89
JOURNAL ARTICLE
Guiyu Li, Wenhui Ma, Xiang Li, Weidong Yang, Zhiyong Quan, Taoqi Ma, Junling Wang, Yunya Wang, Fei Kang, Jing Wang
The uMI Panorama is a novel PET/CT system using silicon photomultiplier and application-specific integrated circuit technologies and providing exceptional spatial and time-of-flight (TOF) resolutions. The objective of this study was to assess the physical performance of the uMI Panorama in accordance with the National Electrical Manufacturers Association (NEMA) NU 2-2018 standard. Methods: Spatial resolution, sensitivity, count rate performance, accuracy, image quality, and TOF resolution were evaluated in accordance with the guidelines outlined in the NEMA NU 2-2018 standard...
February 22, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38388512/total-body-pet-ct-applications-in-cardiovascular-diseases-a-perspective-document-of-the-snmmi-cardiovascular-council
#90
JOURNAL ARTICLE
Riemer H J A Slart, Frank M Bengel, Cigdem Akincioglu, Jamieson M Bourque, Wengen Chen, Marc R Dweck, Marcus Hacker, Saurabh Malhotra, Edward J Miller, Matthieu Pelletier-Galarneau, René R S Packard, Thomas H Schindler, Richard L Weinberg, Antti Saraste, Piotr J Slomka
Digital PET/CT systems with a long axial field of view have become available and are emerging as the current state of the art. These new camera systems provide wider anatomic coverage, leading to major increases in system sensitivity. Preliminary results have demonstrated improvements in image quality and quantification, as well as substantial advantages in tracer kinetic modeling from dynamic imaging. These systems also potentially allow for low-dose examinations and major reductions in acquisition time. Thereby, they hold great promise to improve PET-based interrogation of cardiac physiology and biology...
February 22, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38719242/clinical-implementation-of-total-body-pet-in-china
#91
REVIEW
Yaping Wu, Tao Sun, Yee Ling Ng, Jianjun Liu, Xiaohua Zhu, Zhaoping Cheng, Baixuan Xu, Nan Meng, Yun Zhou, Meiyun Wang
Total-body (TB) PET/CT is a groundbreaking tool that has brought about a revolution in both clinical application and scientific research. The transformative impact of TB PET/CT in the realms of clinical practice and scientific exploration has been steadily unfolding since its introduction in 2018, with implications for its implementation within the health care landscape of China. TB PET/CT's exceptional sensitivity enables the acquisition of high-quality images in significantly reduced time frames. Clinical applications have underscored its effectiveness across various scenarios, emphasizing the capacity to personalize dosage, scan duration, and image quality to optimize patient outcomes...
May 6, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38719241/recent-advances-in-radiotracers-targeting-novel-cancer-specific-biomarkers-in-china-a-brief-overview
#92
REVIEW
Jingming Zhang, Fei Kang, Xiao Wang, Xuejiao Chen, Xing Yang, Zhi Yang, Jing Wang
Radiopharmaceuticals play a critical role in nuclear medicine, providing novel tools for specifically delivering radioisotopes for the diagnosis and treatment of cancers. As the starting point for developing radiopharmaceuticals, cancer-specific biomarkers are important and receive worldwide attention. This field in China is currently experiencing a rapid expansion, with multiple radiotracers targeting novel targets being developed and translated into clinical studies. This review provides a brief overview of the exploration of novel imaging targets, preclinical evaluation of their targeting ligands, and translational research in China from 2020 to 2023, for detecting cancer, guiding targeted therapy, and visualizing the immune microenvironment...
May 6, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38719240/translational-pet-imaging-of-nectin-4-expression-in-multiple-different-cancers-with-68-ga-n188
#93
JOURNAL ARTICLE
Jianhua Zhang, Xiaojiang Duan, Xueqi Chen, Zhuochen Zhang, Hongwei Sun, Jiayin Shou, Guangyu Zhao, Jianxin Wang, Yongsu Ma, Yinmo Yang, Xiaodong Tian, Qi Shen, Wei Yu, Zhisong He, Yan Fan, Xing Yang
Nectin cell adhesion molecule 4 (nectin-4) is a transmembrane protein overexpressed on a variety of cancers and plays an important role in oncogenic and metastatic processes. The nectin-4-targeted antibody-drug conjugate enfortumab vedotin has been approved for treating locally advanced or metastatic urothelial cancer, but the efficacy in other types of cancer remains to be explored. The aim of this study was to evaluate the feasibility of nectin-4-targeted PET imaging with 68 Ga-N188 as a noninvasive method to quantify membranous nectin-4 expression in multiple tumor types-an approach that may provide insight for patient stratification and treatment selection...
May 6, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38719239/the-role-of-total-body-pet-in-drug-development-and-evaluation-status-and-outlook
#94
REVIEW
Xiangxi Meng, Xiangxing Kong, Lei Xia, Runze Wu, Hua Zhu, Zhi Yang
Total-body PET, an emerging technique, enables high-quality simultaneous total-body dynamic PET acquisition and accurate kinetic analysis. It has the potential to facilitate the study of multiple tracers while minimizing radiation dose and improving tracer-specific imaging. This advancement holds promise for enhancing the development and clinical evaluation of drugs, particularly radiopharmaceuticals. Multiple clinical trials are using a total-body PET scanner to explore existing and innovative radiopharmaceuticals...
May 6, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38719238/melanin-targeting-radiotracers-and-their-preclinical-translational-and-clinical-status-from-past-to-future
#95
REVIEW
Xiao Zhang, Zhaoguo Lin, Yuan Feng, Fei Kang, Jing Wang, Xiaoli Lan
Melanin is one of the representative biomarkers of malignant melanoma and a potential target for diagnosis and therapy. With advancements in chemistry and radiolabeling technologies, promising strides have been made to synthesize radiolabeled melanin-binding molecules for various applications. We present an overview of melanin-targeted radiolabeled molecules and compare their features reported in preclinical studies. Clinical practice and trials are also discussed to elaborate on the safety and validity of the probes, and expanded applications beyond melanoma are reviewed...
May 6, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38719237/landscape-of-nuclear-medicine-in-china-and-its-progress-on-theranostics
#96
REVIEW
Weidong Yang, Fei Kang, Yue Chen, Zhaohui Zhu, Feng Wang, Chunxia Qin, Jin Du, Xiaoli Lan, Jing Wang
Nuclear medicine in China started in 1956 and, with the rapid development of the economy and continuous breakthroughs in precision medicine, has made significant progress in recent years. Almost 13,000 staff members in nearly 1,200 hospitals serve more than 3.9 million patients each year. Over the past decade, the radiopharmaceutical industry has developed rapidly, with the initial formation of a complete industrial chain of production of various radiopharmaceuticals for both clinical use and basic research...
May 6, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38719236/pathway-to-approval-of-innovative-radiopharmaceuticals-in-china
#97
REVIEW
Shuxian An, Lu Wang, Fang Xie, Dawei Jiang, Gang Huang, Jianjun Liu, Xiaowei Ma, Weijun Wei
Since the late 1950s, radiopharmaceuticals have been used for diagnosis and treatment in clinical nuclear medicine in China. Over the decades, China has successfully established a relatively sophisticated system for radiopharmaceutical production and management, supported by state-of-the-art facilities. With the rapid growth of the national economy, the radiopharmaceutical market in China is expanding at a remarkable pace. This burgeoning market has led to an escalating demand for clinical-stage radiopharmaceuticals, either produced domestically or imported...
May 6, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38719235/advancing-global-nuclear-medicine-the-role-and-future-contributions-of-china
#98
JOURNAL ARTICLE
Haojun Chen, Kuangyu Shi, Weibo Cai, Sijin Li, Jing Wang
No abstract text is available yet for this article.
May 6, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38719234/fibroblast-activation-protein-inhibitor-tracers-and-their-preclinical-translational-and-clinical-status-in-china
#99
REVIEW
Liang Zhao, Fei Kang, Yizhen Pang, Jianyang Fang, Long Sun, Hua Wu, XiaoLi Lan, Jing Wang, Haojun Chen
Quinoline-based fibroblast activation protein (FAP) inhibitors (FAPIs) have recently emerged as a focal point in global nuclear medicine, underscored by their promising applications in cancer theranostics and the diagnosis of various nononcological conditions. This review offers an in-depth summary of the existing literature on the evolution and use of FAPI tracers in China, tracing their journey from preclinical to clinical research. Moreover, this review also assesses the diagnostic accuracy of FAPI PET for the most common cancers in China, analyzes its impact on oncologic management paradigms, and investigates the potential of FAP-targeted radionuclide therapy in patients with advanced or metastatic cancer...
May 6, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38719233/advantages-and-challenges-of-total-body-pet-ct-at-a-tertiary-cancer-center-insights-from-sun-yat-sen-university-cancer-center
#100
REVIEW
Wanqi Chen, Yinghe Li, Zhijian Li, Yongluo Jiang, Yingpu Cui, Jiling Zeng, Yiwen Mo, Si Tang, Shatong Li, Lei Liu, Yumo Zhao, Yingying Hu, Wei Fan
In recent decades, researchers worldwide have directed their efforts toward enhancing the quality of PET imaging. The detection sensitivity and image resolution of conventional PET scanners with a short axial field of view have been constrained, leading to a suboptimal signal-to-noise ratio. The advent of long-axial-field-of-view PET scanners, exemplified by the uEXPLORER system, marked a significant advancement. Total-body PET imaging possesses an extensive scan range of 194 cm and an ultrahigh detection sensitivity, and it has emerged as a promising avenue for improving image quality while reducing the administered radioactivity dose and shortening acquisition times...
May 6, 2024: Journal of Nuclear Medicine
journal
journal
20164
5
6
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.